Last updated: July 30, 2026
Carboprost tromethamine is an injectable oxytocic used to treat uterine atony after delivery and to manage hemorrhage in obstetric settings. Public clinical-trial visibility is limited, with few active late-stage programs and a commercial profile dominated by established generics and supply-channel dynamics rather than pipeline expansion.
What clinical trials have been conducted for carboprost tromethamine, and what is the latest update (2024–2026)?
Carboprost tromethamine clinical evidence base is largely historical, spanning uterine atony and postpartum hemorrhage (PPH) use in obstetrics, with dosing and administration guided by label-based regimens rather than novel endpoints.
Which trial designs and endpoints recur in carboprost uterine atony studies?
Across older studies, trial structure typically centers on:
- Hemorrhage control endpoints (cessation of bleeding or reduction in blood loss)
- Uterine tone response (clinician-assessed uterine contractions)
- Need for escalation to second-line interventions (mechanical, additional uterotonics, surgical measures)
What is the current status of “new” phase programs?
No widely indexed, late-stage (Phase 3) carboprost tromethamine program with distinctive global endpoints is consistently identifiable from public registries at the 2024–2026 horizon. The practical implication for stakeholders is that near-term market movement is more sensitive to supply continuity, generic competition, and regulatory filings than to new clinical readouts.
What is carboprost tromethamine used for clinically, and how does it perform versus other uterotonics?
Carboprost is used when first-line uterotonics do not achieve adequate uterine tone. It is a prostaglandin F2α analogue, and its clinical role is typically positioned after oxytocin and methylergonovine protocols in hemorrhage algorithms, subject to contraindications.
How is carboprost dosed and administered in practice?
Label-based use generally follows intramuscular (IM) or intramyometrial administration patterns depending on setting and protocol, with repeat dosing if uterine response is inadequate. Market uptake tracks guideline adherence and availability in hospital formularies.
How does carboprost compare with oxytocin, misoprostol, and methylergonovine?
In obstetric protocols:
- Oxytocin is commonly first-line due to broad availability and dosing simplicity.
- Misoprostol is frequently used for resource-limited settings.
- Methylergonovine is an alternative uterotonic with vascular tone effects.
- Carboprost is used for refractory uterine atony when additional prostaglandin pathway stimulation is required.
Practical decision drivers are contraindication profiles (eg, asthma history and bronchospasm risk), route practicality, and supply reliability.
What patents protect carboprost tromethamine, and when do they expire?
Carboprost tromethamine is a long-established small-molecule drug, and patent protection in many markets is dominated by older composition-of-matter and formulation disclosures from the originator era. In practice, the commercial landscape is primarily governed by:
- Generic ANDA/market authorizations in jurisdictions where small-molecule generics are substituted
- Any remaining process- or formulation-related patents in select markets
- Exclusivity tied to specific marketing authorizations rather than to active late-stage pipeline IP
How strong is the patent estate for carboprost by market?
By default for established uterotonics, the patent estate is typically weak for preventing generic entry once primary composition patents have expired. Any remaining IP is more likely to be narrow and formulation- or method-of-use constrained, limiting litigation leverage unless a challenge targets a still-protected specific claim set.
Actionable conclusion: expect minimal IP-driven entry barriers and focus on supply-chain continuity and regulatory status when building market projections.
What is the Orange Book status of carboprost tromethamine in the U.S.?
Carboprost is marketed in the U.S. as an injectable product under established ANDAs. Orange Book listings, when present for specific NDC products, typically show expired or near-expired patent coverage with limited remaining enforceability.
Commercial implication: the U.S. market generally behaves like a mature generic segment with price competition and formulary churn rather than an originality-anchored premium market.
Are there Paragraph IV challenges or carboprost ANDA litigation that affect market entry?
For mature generics like carboprost, market entry timing is more likely to be constrained by:
- Applicant-specific manufacturing validation and stability data
- Market availability of active ingredient and sterile fill-finish capacity
- Court calendars only where still-relevant patents exist
Actionable conclusion: in the absence of high-visibility, recent disputes, near-term entry risk is driven more by supply and regulatory execution than by Paragraph IV-driven delays.
What FDA regulatory pathway applies to carboprost tromethamine, and what does that mean for generic entry risks?
Carboprost is not a novel biologic; generic competitors typically pursue ANDA routes for small-molecule versions.
What does the regulatory pathway imply for speed to market?
For mature, formulation-level generics:
- Approval lags are typically driven by chemistry, manufacturing, and controls (CMC) readiness rather than clinical burden
- Bioequivalence requirements apply to systemically active small-molecules, but injectable routes can reduce variability if formulation and process are aligned
Actionable conclusion: generic entry is usually bottlenecked by manufacturing capacity and quality system timelines.
What formulations are on the market for carboprost tromethamine, and which ones drive demand?
The commercial product is primarily an injectable formulation, typically offered in standard hospital pack sizes. Demand is hospital and institutional, with usage tied to:
- Obstetric care volume
- PPH protocol compliance
- Stocking decisions and contracting
Which administration routes matter for purchasing?
Purchasing behavior favors:
- Predictable shelf life and cold-chain requirements (if any)
- Standardized pack formats that fit emergency obstetric kits
- Consistent dosing availability for protocol-based escalation
Market analysis: How big is the carboprost tromethamine market, and what are the revenue drivers (2024–2029)?
Carboprost market dynamics track PPH incidence treated in hospitals and contracting behavior for generic injectables. The segment is mature, price-competitive, and sensitive to supply interruptions.
Demand drivers
- Increased facility delivery volumes in markets with high hospital birth rates
- Hospital protocol adoption and audit outcomes for PPH pathways
- Stocking of ready-to-use uterotonics in emergency obstetric workflows
Supply and pricing drivers
- Active ingredient availability and sterile manufacturing throughput
- Competitor price erosion in generic tender markets
- Contracting cycles for large hospital systems
Revenue outlook (projection framework)
Because carboprost is a mature generic injectable, projection should be built on:
- Volume stabilization or growth from delivery rates and utilization
- ASP pressure from generic competition
- Occasional step-changes from supply constraints
Practical projection range (directional):
- Base case: low-to-mid single digit annual growth driven by volume offset by ASP erosion
- Downside: flat-to-declining revenue where supply constraints or intensified price competition occur
- Upside: modest growth when tender pricing stabilizes and availability improves
Which companies supply carboprost tromethamine, and how does competition shape pricing?
Carboprost is supplied by multiple generic manufacturers. Competitive structure in mature injectables usually results in:
- Multiple equivalent ANDA holders across the same strength and pack format
- Contract-driven pricing differences rather than brand-level differentiation
- Formulary switching based on tender results and delivery performance
Actionable conclusion: for market entry or scale-up decisions, underwriting should focus on supply reliability metrics and contracting access, not on clinical differentiation.
What competitive landscape exists for uterotonics in postpartum hemorrhage, and how could it substitute for carboprost?
Carboprost competes within an uterotonic basket rather than as a standalone product category.
Substitution risks
- Preference shift to oxytocin or misoprostol when guideline updates prioritize ease of administration and availability
- Increased use of combination protocols where carboprost remains second- or third-line
- Restriction in patient groups with asthma history or prostaglandin sensitivity, affecting utilization rates
How this changes market projections
Substitution is typically partial, not total, given carboprost’s role in refractory uterine atony. Market share volatility is expected with protocol and formulary changes but limited therapeutic elimination.
What does “loss of exclusivity” mean for carboprost, and what timelines matter?
For carboprost, exclusivity concepts are less about near-term “loss dates” and more about:
- Whether any still-enforced patent remains by specific formulation or process
- Whether product-specific exclusivities were tied to specific NDA/ANDA actions in past decades
Actionable conclusion: market timelines are dominated by generic substitution and supply cycles, not imminent exclusivity cliffs.
Biosimilar risk: Is there any biosimilar or advanced biologic pathway threat to carboprost?
No. Carboprost tromethamine is a small molecule prostaglandin F2α analogue, not a biologic product. Biosimilar threat is not applicable.
What is the best generic entry scenario and what are the main barriers for carboprost?
Best-case generic entry
- Obtain ANDA approval with demonstrable CMC equivalence for sterile injectable product
- Secure distribution and tender inclusion in hospital systems
- Maintain consistent supply without stock-outs
Main barriers
- Sterile manufacturing capacity and batch release timelines
- Stability and packaging alignment for injectable products
- Contracting inertia and switching costs in hospital formularies
What patent litigation affects carboprost tromethamine markets?
For mature generics, litigation visibility is usually limited unless a still-relevant patent is asserted against a specific ANDA.
Actionable conclusion: for near-term planning, assume litigation is not the primary timing driver unless a current case is identified against a relevant NDC or patent family.
Key Takeaways
- Carboprost tromethamine is a mature injectable uterotonic with clinical use centered on uterine atony and postpartum hemorrhage protocols, typically as escalation therapy.
- Public clinical development visibility for new late-stage programs is limited, making market movement more sensitive to supply, tender pricing, and regulatory execution than to fresh efficacy readouts.
- Patent leverage is generally low for established small-molecule injectables; competitive pressure comes from generic competition and contracting.
- Revenue projection is best modeled as volume stability offset by ASP erosion, with occasional supply-driven step changes.
- Competitive risk is substitution within the uterotonic class (oxytocin/misoprostol/methylergonovine protocols) rather than biosimilar or biologic displacement.
FAQs
- How do hospital postpartum hemorrhage protocols decide when to use carboprost tromethamine instead of oxytocin or misoprostol?
- Which carboprost tromethamine NDC products have the most price competition in U.S. hospital tenders?
- What manufacturing and sterility bottlenecks most often disrupt supply of injectable oxytocics like carboprost?
- How do contraindications such as asthma history affect carboprost utilization rates and formularies?
- What regulatory markers (CMC changes, labeling updates) most frequently trigger manufacturing delays for generic carboprost?
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed 2026).
- U.S. National Library of Medicine. ClinicalTrials.gov. Studies on carboprost tromethamine. (Accessed 2026).
- StatPearls. Carboprost Tromethamine. (Accessed 2026).
- FDA. Guidance for Industry: ANDA Submissions. (Accessed 2026).
